• 首页
  • 创刊词
  • 期刊介绍
    • 杂志简介
    • 编委会
    • 编辑部
  • 过刊浏览
  • 杂志订阅
    • 订阅须知
    • 在线订阅
  • 在线投稿
    • 投稿指南
    • 年度选题
    • 在线投稿
  • 下载中心
  • 学术交流
    • 研究论坛
    • 学术沙龙
    • 编委会会议
  • 登录
    • 作者登录
    • 审稿登录
    • 编辑登录
    • 读者登录
引用本文:胡颖廉.我国药品安全监管:制度变迁和现实挑战(1949—2005)[J].中国卫生政策研究,2009,2(6):45-51
我国药品安全监管:制度变迁和现实挑战(1949—2005)
投稿时间:2009-05-08  修订日期:2009-05-25  PDF全文浏览  HTML全文浏览
胡颖廉
清华大学公共管理学院
摘要:药品存在多种风险,随着工业化的推进,各国都对药品安全实行严格的政府监管。我国政府从建国伊始就设立药政、药检机构,并对医药行业进行指令性的行政管理,以确保人民群众的药物安全和可及。成立于1998年的国家药监局是国务院机构改革的产物,其在形式上解决了医药领域多头管理、职权交叉、政企不分等问题,并运用行政许可、信息公开等手段对药品安全进行监管,试图达到“以监管为中心,监、帮、促相结合”的政策目标。然而从国家药监局成立至2005年,我国药监领域出现诸多问题,表现为药害事故频发,低水平新药泛滥,行政许可领域腐败现象严重,民族制药工业经济效益不佳,药品使用环节监管无力等。政策目标多元,法律地位模糊,机构声誉不佳,监管能力不足和内部认同度低可以部分地解释这一“没有赢家”的政策结果。
关键词:药品安全  政府监管  历史  机构
Drug safety regulation in China: institutional transition and current challenges (1949—2005)
HU Ying-lian
School of Public Policy & Management, Tsinghua University
Abstract:Drug safety regulation has been the indisputable responsibility of modern states in line with the development of industrialization due to the serious concerns of various risks of drug To realize the accessibility and safety of medicine for the people, Chinese government established drug administrations and drug control institutes national wide after liberation, as well as a central planned authority in administrating the pharmaceutical industry Since the establishment in 1998 by State Council, State Drug Administration (SDA) ended fragmentized authorities and line department in pharmaceutical regulation, which was deemed as a great progress in administrative reform SDA also introduced advanced regulatory tools like administrative license, information disclosure in order to achieve multiple policy goals Unfortunately, continuous corruption cases in drug administrations and serious drug accidents lead observers to believe in a deteriorating trend of drug safety situation during the past decade in China The so called ‘no winner’ policy consequences could partly be explained by multiple unclear policy goals, blurred legal status, uncredited institutional reputation, and weak regulatory capacity
Key words:Drug safety, Government regulation, History, Institution
摘要点击次数: 3346    全文下载次数: 8026
版权所有:《中国卫生政策研究》编辑部
您是本站第62135957位读者 今日访问30次
京ICP备10218182号-6

京公网安备 11010502037852号